All In Biotech

NDA 219070 · Crinetics

Palsonify

Paltusotine Hydrochloride · Oral

NovelOrphan

CDER novel approval, Sep 25, 2025: To treat acromegaly in adults who had an inadequate response to surgery and/or for whom surgery is not an option

Last checked: Nov 20, 2026Latest source record: Sep 25, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2025

Sep 25, 2025

Approved uses

1

Original approval plus efficacy supplements

Registered trials

7

3 Phase 3, 0 recruiting

FAERS reports

238

36 serious, 1 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Sep 16, 2025.

PALSONIFY is indicated for the treatment of adults with acromegaly who had an inadequate response to surgery and/or for whom surgery is not an option. PALSONIFY is a somatostatin receptor agonist indicated for the treatment of adults with acromegaly who had an inadequate response to surgery and/or for whom surgery is not an option ( 1 ).

Mechanism: Similar to the natural hormone somatostatin, paltusotine suppresses growth hormone (GH) and insulin-like growth factor-1 (IGF-1) secretion. Paltusotine exerts its pharmacological activity via selective agonism (>4000-fold) at somatostatin receptor 2 (SSTR2) and exhibits little or no affinity for other SST receptor subtypes. Paltusotine inhibited cyclic adenosine monophosphate accumulation via human SSTR2 activation with an average drug (agonist) concentration that results in half-maximal response (EC 50 ) of 0.25 nM.

Therapeutic areas: Endocrinology and women's health

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Sep 25, 2025 Original approval · Type 1 - New Molecular Entity NovelOrphanLabelLetterReview
2 products under this application
  • PALSONIFY · PALTUSOTINE HYDROCHLORIDE EQ 20MG BASE · TABLET, ORAL · Prescription
  • PALSONIFY · PALTUSOTINE HYDROCHLORIDE EQ 30MG BASE · TABLET, ORAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Paltusotine" as an intervention, any sponsor and status, largest first.

All 7 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • diarrhoea52
  • fatigue28
  • product dose omission issue28
  • nausea27
  • abdominal discomfort25
  • arthralgia21
  • headache21
  • abdominal pain16
  • abdominal pain upper15
  • gastrointestinal disorder14
  • off label use14
  • therapy interrupted14

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20252
2026236

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 9 on PubMed

Sponsor: Crinetics

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.